Cullinan Therapeutics Past Earnings Performance

Past criteria checks 0/6

Cullinan Therapeutics's earnings have been declining at an average annual rate of -25.4%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 36.1% per year.

Key information

-25.4%

Earnings growth rate

51.3%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	-36.1%
Return on equity	-23.2%
Net Margin	n/a
Last Earnings Update	30 Sep 2024

Recent past performance updates

No updates

Recent updates

Cullinan Therapeutics: Casting A Wide Net With Their Pipeline

Jan 08

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Nov 20

Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease

Aug 30

Checking Into Cullinan Therapeutics

Jun 09

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Apr 23

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Jun 24

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Mar 05

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Oct 08

Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development

Jun 30

Cullinan Oncology (CGEM) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow

Jun 05

Cullinan initiated Buy at H.C. Wainwright on pipeline strength

Feb 02

Revenue & Expenses Breakdown

How Cullinan Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:CGEM Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	0	-144	50	137
30 Jun 24	0	-142	48	136
31 Mar 24	0	-132	44	127
31 Dec 23	0	-153	42	148
30 Sep 23	0	-156	45	135
30 Jun 23	0	-142	44	120
31 Mar 23	0	65	43	120
31 Dec 22	0	111	40	92
30 Sep 22	0	105	40	92
30 Jun 22	0	113	36	85
31 Mar 22	0	-78	32	70
31 Dec 21	19	-66	29	58
30 Sep 21	19	-61	28	60
30 Jun 21	19	-54	24	57
31 Mar 21	19	-47	21	51
31 Dec 20	0	-52	17	43
30 Sep 20	0	-28	6	24
30 Jun 20	0	-25	6	19
31 Mar 20	0	-21	6	17
31 Dec 19	0	-21	5	17

Quality Earnings: CGEM is currently unprofitable.

Growing Profit Margin: CGEM is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: CGEM is unprofitable, and losses have increased over the past 5 years at a rate of 25.4% per year.

Accelerating Growth: Unable to compare CGEM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CGEM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).

Return on Equity

High ROE: CGEM has a negative Return on Equity (-23.17%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/31 13:55
End of Day Share Price	2025/01/31 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cullinan Therapeutics, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Julian Harrison	BTIG
Kaveri Pohlman	BTIG
Thomas Shrader	BTIG

Cullinan Therapeutics Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy

New major risk - Shareholder dilution

Cullinan Therapeutics: Casting A Wide Net With Their Pipeline

President recently sold US$100k worth of stock

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Cullinan Therapeutics, Inc. Announces Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, to Be Presented at ACR Convergence 2024

Cullinan Therapeutics, Inc. to Present Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, at ACR Convergence 2024

Cullinan Therapeutics, Inc Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Cullinan Therapeutics, Inc. Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

Chief Scientific Officer notifies of intention to sell stock

Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease

Independent Director exercised options to buy US$402k worth of stock.

Checking Into Cullinan Therapeutics

Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib

Independent Director exercised options to buy US$2.4m worth of stock.

Consensus EPS estimates upgraded to US$3.01 loss

Cullinan Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Cullinan Therapeutics, Inc. Announces Board Changes

Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates increase by 19%

Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Price target increased by 13% to US$28.71

Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in funding

Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024

Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024

Chief Business Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Cullinan Oncology, Inc. to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Price target decreased by 11% to US$25.25

New minor risk - Profitability

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. Announces the Launch of the REZILIENT3 Trial

Investor sentiment improves as stock rises 17%

High number of new and inexperienced directors

Chief Development Officer notifies of intention to sell stock

Investor sentiment improves as stock rises 16%

Cullinan Oncology, Inc. Announces First Clinical Data from its Phase 1 Study of CLN-619 in Patients with Advanced Solid Tumors

Cullinan Oncology, Inc. Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, Novel T-Cell Engager for Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Investor sentiment deteriorated over the past week

Chief Development Officer notifies of intention to sell stock

Price target decreased to US$34.00

Cullinan Oncology Appoints of David P. Ryan to Its Board of Directors

Investor sentiment improved over the past week

Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years

Cullinan Oncology: One Of The Leaders In Cancer Treatment Development

Cullinan Oncology grants stock options for 125.7K shares

Cullinan Oncology, Inc. Appoints Jacquelyn Sumer as Chief Legal Officer

Insider recently sold US$712k worth of stock

Chief Business Officer notifies of intention to sell stock

Chief Business Officer notifies of intention to sell stock

Cullinan Oncology, Inc.(NasdaqGS:CGEM) dropped from Russell 2000 Growth Index

Insider recently sold US$1.3m worth of stock

Taiho Pharmaceutical Co., Ltd. completed the acquisition of Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM).

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

President recently bought US$100k worth of stock

Insider recently sold US$4.0m worth of stock

Price target decreased to US$39.25

Forecast to breakeven in 2022

Taiho Pharmaceutical Co., Ltd. entered into a Share Purchase Agreement to acquire Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM) for approximately $400 million.

Cullinan Oncology, Inc., Annual General Meeting, Jun 22, 2022

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients

Cullinan Oncology, Inc. to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio At American Association for Cancer Research 2022

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Cullinan Oncology, Inc. Announces Management Appointments

Price target decreased to US$47.75

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Cln-081 for the Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Strategic Advisor notifies of intention to sell stock

Cullinan Oncology, Inc. Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients

CFO & Treasurer exercised options and sold US$166k worth of stock

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Chief Development Officer of Biologics exercised options and sold US$81k worth of stock

CFO & Treasurer exercised options and sold US$363k worth of stock